Phase IIa Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Infigratinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 02 Oct 2017 Planned End Date changed from 1 May 2018 to 1 May 2020.
- 02 Oct 2017 Planned primary completion date changed from 1 May 2018 to 1 May 2020.
- 02 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Mar 2018.